化疗相关乙肝病毒再激活的诊治现状

全球近1／3的人口感染过乙肝，多数分布在许多亚洲国家中。我国是乙肝大国，我国现有的慢性乙肝病毒感染者约9300万人。化学治疗是肿瘤综合治疗中的一项重要手段，随着人口寿命增加和癌症发病率逐年增长，癌症患者接受化疗治疗后，乙肝病毒再激活已经成为癌症化疗中不可忽视的问题。再激活可能导致严重肝损害，迫使患者推迟化疗甚至死于肝衰竭。化疗病人乙肝病毒再激活能够被核苷（酸）类药物有效地预防，但预防及治疗的最佳策略仍在研究中。

Diagnosis and management of the hepatitis B reactivation in patients receiving cytotoxic chemotherapy

Nearly one third of the world＇s population have been infected with hepatitis B and the virus is endemic in many Asian countries. China has a high prevalence of HBV, and the number of chronic carriers reaches to ninetythree million. Chemotherapy is an important component in comprehensive treatment of tumor and with increasing life expectancy and the expected global increase in cancer, chemotherapy induced reactivation of HBV is likely to become an increasing problem. Severe liver damage causing by HBV reactivation may also result m a delay to complete chemotherapy or even death of liver failure. It has been recognized that HBV reactivation following chemotherapy can effectively he prevented by nucleoside analogue. However, the optimal method of prevention and treatment have not been fully clarified.